Frederick Pfalzgraf, MD
Rheumatology · Herrin, ILNPI 1659385581
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 70.6% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $12,043 and has fallen 83.4% since, to $1,996 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 706 payments — averaging $51.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- UCB, Inc.$2K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$1K
- Novartis$1K
- Pfizer$1K
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$19,05052%
- Travel & lodging$2,7317%
- Food & beverage$14,49840%
- Education$3161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $25,820 |
| UCB, Inc. | 84 | $1,968 |
| Amgen(2 entities) | 83 | $1,561 |
| Mallinckrodt Hospital Products Inc. | 43 | $1,433 |
| Novartis | 65 | $1,422 |
| Pfizer | 108 | $1,238 |
| Sanofi | 22 | $645 |
| Lilly USA, LLC | 29 | $623 |
| AstraZeneca(2 entities) | 29 | $547 |
| E.r. Squibb & Sons, L.L.C. | 26 | $422 |
| Bristol Myers Squibb | 30 | $179 |
| Johnson & Johnson | 13 | $168 |
| Mallinckrodt Enterprises LLC | 9 | $108 |
| Genentech, Inc. | 1 | $105 |
| GSK | 2 | $104 |
| Aurinia Pharma U.S., Inc. | 3 | $61 |
| Genentech USA, Inc. | 3 | $53 |
| Organon | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,594 in reported general payments places this provider in the 90th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 30 | $3,151,490 |
| Humira(Cf) PenAdalimumab | 97 | $1,063,233 |
| Enbrel SureclickEtanercept | 24 | $396,439 |
| Enbrel MiniEtanercept | 26 | $360,622 |
| EnbrelEtanercept | 38 | $339,933 |
| RinvoqUpadacitinib | 35 | $264,512 |
| Humira(Cf)Adalimumab | 13 | $167,660 |
| Xeljanz XrTofacitinib Citrate | 27 | $149,680 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $114,468 |
| KevzaraSarilumab | 25 | $107,762 |
| XeljanzTofacitinib Citrate | 18 | $105,337 |
| HumiraAdalimumab | 11 | $89,524 |
| Humira PenAdalimumab | 12 | $77,663 |
| OtezlaApremilast | 12 | $59,472 |
| ActemraTocilizumab | 11 | $25,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,433 | $3,151,49030 claims |
| AbbVieRinvoq, Humira(Cf), Humira, Savella | $25,820 | $539,55279 claims |
| AmgenEnbrel, Otezla | $1,561 | $399,40550 claims |
| SanofiKevzara | $645 | $107,76225 claims |
| PfizerXeljanz | $1,238 | $105,33718 claims |
| Genentech, Inc.Actemra | $105 | $25,53611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 rheumatology providers in Illinois.
Other rheumatology in Herrin
- Manish JainChicago$1.9M
- Lori SiegelBannockburn$1.5M
- Alfonso BelloGlenview$611K
- Theodore PincusChicago$524K
- Angela CrowleyWillowbrook$483K
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Jeffrey HorvathSpringfield$246K
- Robert HozmanSkokie$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.